Borneo Pacific Pharmaceuticals Ltd

Borneo Pacific Pharmaceuticals Ltd, established in 1996 and operational since 1997, is a leading pharmaceutical importer and distributor based in Port Moresby, Papua New Guinea. The company is headquartered at Lot 22, Section 496, Hohola Ward, Gordons, Port Moresby, with a postal address of P.O. Box 1614, Port Moresby. As of 2026, Borneo Pacific Pharmaceuticals Ltd employs approximately 50 staff members and generates sales of around $5.33 million USD. The company operates as a primary wholesaler, sourcing a diverse range of pharmaceutical products to meet the healthcare needs of Papua New Guinea.

Borneo Pacific Pharmaceuticals Ltd maintains a centralized distribution hub in Port Moresby, which serves as the focal point for its logistics operations. While specific details about additional warehouse locations are not publicly disclosed, the company's strategic position in the capital city enables efficient distribution throughout Papua New Guinea. The firm has demonstrated its logistics capabilities by handling a total of 11 shipments from India between 2022 and 2026, indicating a well-established supply chain.

In Papua New Guinea's pharmaceutical supply chain, Borneo Pacific Pharmaceuticals Ltd functions as a primary wholesaler. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. Between 2022 and 2026, Borneo Pacific Pharmaceuticals Ltd imported a total of 11 shipments from India, encompassing 133 unique formulations. This extensive portfolio underscores its significant role in supplying a wide array of pharmaceutical products to meet the diverse healthcare needs of the nation.

Borneo Pacific Pharmaceuticals Ltd exhibits a high degree of sourcing concentration, with 100% of its pharmaceutical imports from India. Between 2022 and 2026, the company imported a total of 11 shipments from India, encompassing 133 unique formulations. This concentrated sourcing strategy may offer benefits such as streamlined logistics and potentially favorable pricing agreements. However, it also introduces risks associated with over-reliance on a single supplier base, including exposure to geopolitical tensions, supply chain disruptions, and currency fluctuations. The stability of this relationship is crucial; any significant disruptions in the Indian pharmaceutical sector could impact Borneo Pacific Pharmaceuticals Ltd's ability to meet domestic demand.

The resilience of Borneo Pacific Pharmaceuticals Ltd's Indian supply chain is a critical factor in its operational stability. While the company has established relationships with multiple Indian suppliers, including BDH Industries Limited, IPCA Laboratories Limited, and Mylan Laboratories Limited, the exact number of unique suppliers is not specified in the available data. The company's import data indicates a diversified sourcing strategy within India, which can mitigate risks associated with single-source dependency. However, the overall resilience is contingent upon the reliability and compliance of these suppliers, as well as the robustness of the shipping routes and logistics infrastructure. Ensuring that all suppliers adhere to international Good Manufacturing Practices (GMP) and maintaining alternative sourcing options are essential strategies to enhance supply chain resilience.

Borneo Pacific Pharmaceuticals Ltd's concentrated sourcing pattern from India positions it to leverage cost efficiencies and strong supplier relationships. However, this strategy also exposes the company to risks associated with over-reliance on a single supplier base. For Indian exporters, this presents an opportunity to strengthen existing partnerships and explore avenues for expanding their product offerings to Borneo Pacific Pharmaceuticals Ltd. Diversifying the product range and ensuring compliance with international quality standards can enhance the attractiveness of Indian exports to this key importer.

In Papua New Guinea, the regulation of pharmaceutical imports is overseen by the Pharmaceutical Services Standards Branch (PSSB) of the National Department of Health. The PSSB is responsible for administering and implementing the Medicines and Cosmetics Act 1999 and its regulations, ensuring that medicinal products and medical devices are safe, effective, and of good quality for use by the population. (health.gov.pg) The Medicines and Cosmetics Act 1999 provides the legal framework for the registration, importation, and distribution of pharmaceutical products in the country. Additionally, the Drugs Regulations 1958, made under the Drugs Act 1952, outline specific requirements and standards for drugs, including importation procedures and compliance with established standards. (wipo.int)

Import licensing in Papua New Guinea is governed by the Medicines and Cosmetics Act 1999 and the Drugs Regulations 1958. To import restricted drugs, an importer must obtain a drug import license from the Commissioner General, which is subject to specific conditions and requirements. (customs.gov.pg) Importers are also required to ensure that their products comply with international Good Manufacturing Practices (GMP). The Pharmaceutical Society of Papua New Guinea provides guidelines on GMP clearance, emphasizing the importance of adhering to recognized standards to ensure the quality and safety of imported medicines.

Imported pharmaceutical products must undergo batch testing and meet stability requirements as stipulated by the PSSB to ensure their safety and efficacy. Labeling requirements include the use of the English language, as it is the official language of Papua New Guinea. Additionally, serialization mandates may be enforced to enhance traceability and prevent counterfeit products from entering the market. These measures are part of the regulatory framework designed to uphold the integrity of the pharmaceutical supply chain and protect public health.

Between 2024 and 2026, there have been no publicly disclosed policy changes affecting Indian pharmaceutical imports into Papua New Guinea. The regulatory environment remains stable, with existing laws and regulations continuing to govern the importation and distribution of pharmaceutical products. Importers are advised to stay informed about any potential changes and ensure ongoing compliance with all applicable regulations.

Borneo Pacific Pharmaceuticals Ltd's focus on antimalarial and antiparasitic products, particularly Primaquine, Pyrimethamine, and Sulfadoxine, aligns with the significant public health challenges posed by malaria and other parasitic diseases in Papua New Guinea. The company's import data indicates that these products constitute 100% of its pharmaceutical imports from India between 2022 and 2026, with Primaquine alone accounting for 11.9% of the total import value. This strategic focus underscores the company's commitment to addressing critical health needs and its responsiveness to market demand for effective treatments.

Borneo Pacific Pharmaceuticals Ltd's sourcing strategy is centered on importing generic drug formulations from India, a country renowned for its robust pharmaceutical manufacturing sector. The company's preference for finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, reflects a strategic decision to provide ready-to-use products that meet the diverse needs of the Papua New Guinea market. India's adherence to international GMP standards and its competitive pricing further enhance the attractiveness of Indian products in Borneo Pacific Pharmaceuticals Ltd's procurement strategy.

Based on its product mix, Borneo Pacific Pharmaceuticals Ltd primarily serves the wholesale distribution segment of the Papua New Guinea market. By importing and distributing a range of pharmaceutical products, the company supplies hospitals, clinics, pharmacies, and other healthcare providers across the nation. Its strategic focus on antimalarial and antiparasitic medications positions it as a key player in addressing the country's public health priorities.

There is a realistic opportunity for new Indian suppliers to engage with Borneo Pacific Pharmaceuticals Ltd, particularly in the areas of antimalarial and antiparasitic medications. The company's concentrated sourcing pattern from India indicates a preference for established relationships, but also suggests potential for diversification within the Indian supplier base. Indian exporters can explore this opportunity by ensuring compliance with international quality standards, obtaining necessary certifications, and demonstrating the efficacy and safety of their products.

Indian exporters seeking to supply Borneo Pacific Pharmaceuticals Ltd and the Papua New Guinea market must obtain the necessary import licenses and ensure their products comply with international GMP standards. Adherence to the Medicines and Cosmetics Act 1999 and the Drugs Regulations 1958 is mandatory. Additionally, products must meet batch testing and stability requirements, and labeling must be in English. Serialization may also be required to enhance traceability. Maintaining these standards is essential for successful market entry and ongoing compliance.

Indian exporters should initiate engagement with Borneo Pacific Pharmaceuticals Ltd by establishing direct communication with key decision-makers, such as the President & Chief Executive Officer, Michael Robinson. Participating in relevant tenders and responding to Requests for Proposals (RFPs) can provide avenues for collaboration. Develop